7 completed, 2 recruiting. 4 Phase 3, 3 Phase 2, 2 Phase 1.
By phase and status
Follow Tozorakimab: new trials by email Literature Review of Tozorakimab trials Research Report on Tozorakimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
Placebo, Tozorakimab - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Completed | AstraZeneca | 98 | 2025-04-12 | 2026-07-14 |
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device - Healthy Participants | Phase 1 | Completed | AstraZeneca | 254 | 2025-04-07 | 2025-12-02 |
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Tozorakimab, Placebo - Asthma | Phase 2 | Recruiting | AstraZeneca | 540 | 2025-03-26 | 2026-09-25 |
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
Tozorakimab - Healthy Participants | Phase 1 | Completed | AstraZeneca | 46 | 2024-04-08 | 2024-09-19 |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Placebo, Tozorakimab - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 1454 | 2023-09-22 | 2026-07-24 |
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Tozorakimab, Placebo - Viral Lung Infection and Acute Respiratory Failure | Phase 3 | Recruiting | AstraZeneca | 3527 | 2022-12-13 | 2026-10-02 |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Tozorakimab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 1172 | 2022-02-07 | 2026-04-16 |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Tozorakimab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | AstraZeneca | 1132 | 2022-01-03 | 2026-04-16 |
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Tozorakimab, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis | Phase 2 | Completed | AstraZeneca | 137 | 2020-12-14 | 2025-02-27 |
Conditions studied
Pulmonary Disease, Chronic Obstructive (6) · Asthma (2) · Inflammation (2) · Bronchitis, Chronic (1) · COVID-19 (1) · Coronavirus Infections (1) · Infections (1) · Influenza, Human (1) · Lung Diseases (1) · Respiratory Distress Syndrome (1) · Respiratory Tract Infections (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Sponsors
AstraZeneca (9)
Countries
United States (7) · Germany (6) · Hungary (5) · Spain (5) · United Kingdom (5) · Argentina (4) · Brazil (4) · Canada (4) · China (4) · Denmark (4) · France (4) · Greece (4) · India (4) · Israel (4) · Italy (4)
Results publications
PMID 42476723, PMID 42708515
NIH funding
2023 (3)